• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Prime Medicine Inc (NQ: PRME )

    3.410 -0.020 (-0.58%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,428,378
    Open 3.430
    Bid (Size) 3.330 (9)
    Ask (Size) 3.450 (2)
    Prev. Close 3.430
    Today's Range 3.330 - 3.530
    52wk Range 3.280 - 9.860
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
    Changes are afoot at the company, and investors welcomed them. 
    Via The Motley Fool
    Dow Dips 300 Points; Emcore Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities

    Performance

    YTD
    -61.07%
    -61.07%
    1 Month
    -11.66%
    -11.66%
    3 Month
    -34.92%
    -34.92%
    6 Month
    -41.11%
    -41.11%
    1 Year
    -60.80%
    -60.80%

    More News

    Read More
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Prime Medicine Unveils Strategically Focused Pipeline
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
    From Prime Medicine, Inc.
    Via GlobeNewswire
    2 Growth Stocks That Could Make You Richer
    Via The Motley Fool
    Prime Medicine to Participate in Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    PRME Stock Earnings: Prime Medicine Misses EPS for Q2 2024
    Via InvestorPlace
    Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine to Present at Upcoming Investor Conferences
    From Prime Medicine, Inc.
    Via GlobeNewswire
    If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
    Via InvestorPlace
    Exposures Product Safety
    Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
    Via The Motley Fool
    Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
    Via InvestorPlace
    Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
    Via InvestorPlace
    Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    From Prime Medicine, Inc.
    Via GlobeNewswire
    PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024
    Via InvestorPlace
    Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
    From Prime Medicine, Inc.
    Via GlobeNewswire
    Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.